Indications of Ponatinix 45 mg:
Ponatinix, a kinase inhibitor, is indicated for the treatment of adult patients diagnosed with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Ph+ ALL who have not responded to other tyrosine kinase inhibitor (TKI) therapy. It is also prescribed for adult patients with T315I-positive CML (in chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Therapeutic Class:
Tyrosine Kinase Inhibitor

Pharmacology:
Ponatinix is a kinase inhibitor that targets ABL and T315I mutant ABL tyrosine kinase activity, along with various other kinases such as VEGFR, PDGFR, FGFR, EPH receptors, SRC families of kinases, and KIT, RET, TIE2, and FLT3. It inhibits the viability of cells expressing native or mutant BCR-ABL, including T315I, and reduces tumor size in mice expressing these mutations.

Dosage & Administration of Ponatinix 45 mg:
The recommended dose is 45 mg taken orally once daily with or without food. For patients with hepatic impairment, the recommended dose is 30 mg orally once daily. Dosage modification or interruption may be necessary for hematologic and non-hematologic toxicity.

Contraindications:
None

Side Effects of Ponatinix 45 mg:
Common non-hematologic adverse reactions (≥20%) include abdominal pain, rash, constipation, headache, dry skin, arterial occlusion, fatigue, hypertension, pyrexia, arthralgia, nausea, diarrhea, lipase increased, vomiting, myalgia, and pain in extremity.

Pregnancy & Lactation:
Ponatinix can cause fetal harm when administered to pregnant women based on its mechanism of action and findings in animals. Its use in pregnant women is not recommended. Additionally, there is insufficient data on its presence in human milk, its effects on the breastfed infant, or milk production.

Storage Conditions:
Store Ponatinix at room temperature between 20°C to 25°C.

Use In Special Populations:
Safety and effectiveness of Ponatinix have not been established in pediatric patients.